I

nvesting in biotech startups is a laborious business.

Venture capitalists spend months poring over data before deciding whether to back a fledgling company. They’ll scour the scientific literature for signs that the core ideas are valid. They’ll call in the founding team for interminable grillings. They may even hire outside researchers to try to replicate key experiments.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.